Article
Combination of Osimertinib and Anlotinib May Overcome the Resistance Mediated by in cis…
OncoTargets and Therapy · 2021 · Zhou R, Song L, Zhang W, Shao L, Li X, Li X
Key facts
| Title | Combination of Osimertinib and Anlotinib May Overcome the Resistance Mediated by in cis EGFR T790M-C797S in NSCLC: A Case Report |
|---|---|
| First author | Zhou R, Song L, Zhang W, Shao L, Li X, Li X |
| Journal | OncoTargets and Therapy |
| Published | Apr 28, 2021 |
| DOI | 10.2147/OTT.S298655 |
| Devices mentioned | 214044 |
At a glance
- 1–9 FDA submissions mentioned
- None Product codes mentioned
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Literature
Peer-reviewed and preprint literature indexed by Orca1 and linked to the FDA submissions and product codes each article mentions. Only bibliographic details are shown here.
Source: Publisher and PubMed metadata; device mentions identified by Orca1